Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma Biotechnology's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2026 was $4.5 Mil.
Puma Biotechnology's quarterly Long-Term Capital Lease Obligation
declined
from Sep. 2025 ($4.9 Mil) to Dec. 2025 ($4.7 Mil) and
declined
from Dec. 2025 ($4.7 Mil) to Mar. 2026 ($4.5 Mil).
Puma Biotechnology's annual Long-Term Capital Lease Obligation
declined
from Dec. 2023 ($7.0 Mil) to Dec. 2024 ($1.5 Mil) but then
increased
from Dec. 2024 ($1.5 Mil) to Dec. 2025 ($4.7 Mil).
Puma Biotechnology (NAS:PBYI) Long-Term Capital Lease Obligation Explanation
Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.
Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:
1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.
Puma Biotechnology Long-Term Capital Lease Obligation Related Terms
Puma Biotechnology Long-Term Capital Lease Obligation Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's Long-Term Capital Lease Obligation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology Long-Term Capital Lease Obligation Chart
What does a Long-Term Capital Lease Obligation of $4.5 Mil mean?
Puma Biotechnology (PBYI) has a Long-Term Capital Lease Obligation of $4.5 Mil as of Mar. 2026. Capital leases are leases where a finance company is typically the legal owner of the asset during the lease term. View historical data on Puma Biotechnology and its competitors.
Is Puma Biotechnology's Long-Term Capital Lease Obligation too high?
Puma Biotechnology's current Long-Term Capital Lease Obligation is $4.5 Mil. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Long-Term Capital Lease Obligation compare to EVMN and OCGN?
Puma Biotechnology's Long-Term Capital Lease Obligation of $4.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Capital Lease Obligation for a Biotechnology company?
A good Long-Term Capital Lease Obligation depends on the Biotechnology industry context. However, Long-Term Capital Lease Obligation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Capital Lease Obligation mean?
A high Long-Term Capital Lease Obligation can signal that a stock is expensive relative to its fundamentals. Capital leases are leases where a finance company is typically the legal owner of the asset during the lease term. View historical data on Puma Biotechnology and its competitors. Puma Biotechnology's current Long-Term Capital Lease Obligation is $4.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.78 — trading 132.9% above its estimated fair value. The current Long-Term Capital Lease Obligation is $4.5 Mil. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Capital Lease Obligation calculated?
Long-Term Capital Lease Obligation is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Long-Term Capital Lease Obligation is $4.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.78 is trading 132.9% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
Long-Term Capital Lease Obligation: $4.5 Mil
GF Value™: $3.34 vs. price of $7.78 (132.9% above fair value)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
Long-Term Capital Lease Obligation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
